12/10
09:19 am
lxrx
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851 [Yahoo! Finance]
Low
Report
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851 [Yahoo! Finance]
12/10
08:30 am
lxrx
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851
Low
Report
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851
12/5
10:13 am
lxrx
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum [Yahoo! Finance]
Low
Report
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum [Yahoo! Finance]
12/5
08:30 am
lxrx
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum
Low
Report
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum
12/3
10:37 am
lxrx
Lexicon Pharmaceuticals Has Multiple Paths To Upside, But Formidable Hurdles As Well [Seeking Alpha]
Low
Report
Lexicon Pharmaceuticals Has Multiple Paths To Upside, But Formidable Hurdles As Well [Seeking Alpha]
11/26
07:43 am
lxrx
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences [Yahoo! Finance]
Low
Report
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences [Yahoo! Finance]
11/25
06:03 pm
lxrx
Lexicon Pharmaceuticals, Inc. (LXRX) Makes Progress in Product Pipeline Development [Yahoo! Finance]
Low
Report
Lexicon Pharmaceuticals, Inc. (LXRX) Makes Progress in Product Pipeline Development [Yahoo! Finance]
11/25
08:30 am
lxrx
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences
Low
Report
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences
11/15
06:48 am
lxrx
Lexicon Pharmaceuticals: A Lottery Ticket With 3 Chances To Win [Seeking Alpha]
Low
Report
Lexicon Pharmaceuticals: A Lottery Ticket With 3 Chances To Win [Seeking Alpha]
11/11
08:30 am
lxrx
Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference
High
Report
Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference
11/8
02:47 pm
lxrx
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025 [Yahoo! Finance]
High
Report
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025 [Yahoo! Finance]
11/8
02:30 pm
lxrx
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025
High
Report
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025
11/6
07:30 am
lxrx
Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates
Low
Report
Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates
11/4
08:30 am
lxrx
Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans
Low
Report
Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans
10/30
08:30 am
lxrx
Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
Low
Report
Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
10/14
08:00 am
lxrx
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit
Neutral
Report
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit
10/9
09:30 am
lxrx
Former FDA, Industry Leaders Launch Canal Row Advisors to Provide Clients With Strategic Insight And Actionable Guidance In An Increasingly Complex Regulatory Landscape
High
Report
Former FDA, Industry Leaders Launch Canal Row Advisors to Provide Clients With Strategic Insight And Actionable Guidance In An Increasingly Complex Regulatory Landscape
10/8
08:12 am
lxrx
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain [Yahoo! Finance]
Low
Report
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain [Yahoo! Finance]
10/8
07:59 am
lxrx
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain
Medium
Report
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain
10/4
03:06 am
lxrx
Lexicon Pharmaceuticals (NASDAQ:LXRX) was upgraded by analysts at
Wall S
Medium
Report
Lexicon Pharmaceuticals (NASDAQ:LXRX) was upgraded by analysts at
Wall S
9/22
04:24 pm
lxrx
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes [Yahoo! Finance]
Low
Report
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes [Yahoo! Finance]
9/22
04:00 pm
lxrx
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
Medium
Report
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes